Melsi

Indications for use:

Non-steroidal anti-inflammatory and antirheumatic drugs. Oxicams. Short-term symptomatic treatment of exacerbation of osteoarthritis. Long-term symptomatic treatment of rheumatoid arthritis and ankylosing spondylitis.

Contraindications

• Hypersensitivity to meloxicam or other constituents of the drug, to active substances with a similar effect, such as NSAIDs, acetylsalicylic acid. Meloxicam should not be prescribed to patients who have experienced symptoms of asthma, nasal polyps, angioedema, or urticaria after taking acetylsalicylic acid or other NSAIDs;
• gastrointestinal bleeding or perforation associated with previous NSAID therapy in history;
• a history of active or recurrent ulcer/bleeding (two or more separate confirmed cases of ulcer or bleeding);
• severe liver failure;
• severe renal failure without dialysis;
• gastrointestinal bleeding, history of cerebrovascular bleeding, or other disorders
• blood clotting;
• severe heart failure;
• contraindicated for the treatment of perioperative pain in coronary artery bypass grafting (CABG).
• III trimester of pregnancy;
• the patient’s age is up to 16 years.

Method of administration and dosage.

Used internally.
The daily amount of the drug should be used once, washed down with water or other liquid, during meals.
Adverse reactions can be minimized by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms. The patient’s need for symptomatic relief and response to treatment should be periodically assessed.
Exacerbation of osteoarthritis:
7.5 mg / day (1 tablet 7.5 mg or half a tablet 15 mg). If necessary, the dose can be increased to 15 mg / day (1 tablet 15 mg or 2 tablets 7.5 mg).
Rheumatoid arthritis, ankylosing spondylitis:
15 mg / day (1 tablet 15 mg or 2 tablets 7.5 mg).
See the section “Special patient categories”.
According to the therapeutic effect, the dose can be reduced to 7.5 mg/day (1 tablet 7.5 mg or half a tablet 15 mg).
Exceed the dose of 15 mg/day.
Special categories of patients.
Elderly patients and patients with an increased risk of adverse reactions.
The recommended dose for long-term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with an increased risk of developing adverse reactions should start treatment with 7.5 mg per day.
Renal failure
For patients with severe renal impairment on dialysis, the dose should not exceed 7.5 mg per day. Patients with mild to moderate renal impairment (namely, patients with creatinine clearance of 25 ml/min) do not require dose reduction (for patients with severe renal impairment without dialysis, see section “Contraindications”).
Liver failure.
Patients with mild to moderate hepatic impairment do not need to reduce the dose (for patients with severe hepatic impairment, see section “Contraindications”).

Children.
Contraindicated in children under 16 years of age.